NORDIC | BIOTECH & HEALTHCARE Your insights into listed Danish & Nordic biotech & healthcare stocks.
In the past week, the Nordic biotech and healthcare stocks declined 3.7%. Many companies had double-digit declines without any negative news. Biosergen delivered encouraging results in drug-resistant fungal infections in their first cohort with BSG005. On the other hand, Gubra announced they discontinued an obesity project with Boehringer Ingelheim. Finally, the three best-performing healthcare stocks delivered returns of 23-33% – fairly compared to previous weeks.
Only 6 of the 22 Danish biotech companies had a positive share price development in the past week and 11 companies have had a positive share price performance year-to-date. Obesity continues to drive the best performances with Gubra, Zealand Pharma, and Pila Pharma having strong YTD performance. Five Danish healthcare stocks with +100% YTD return.
Danish company news
No news the past week – However, this morning it was announced reimbursement coverage for CADScor is now possible in the U.S. making the stock soar
No news the past week
Biosergen Completes First Cohort of BSG005 Clinical Trial, Shows Promising Potential in Drug-Resistant Fungal Infections (Link)
No news the past week
CS MEDICA Achieves Key Milestone in MDR Compliance with Finalized Classification, Solidifying Unique Market Position for Medical Devices (Link)
No news the past week
No news the past week
Evaxion announces business update and third quarter 2024 financial results (Link)
No news the past week
No news the past week
No news the past week
Gubra announces discontinuation of development of NYP2 in obesity with Boehringer Ingelheim (Link)
No news the past week
No news the past week
No news the past week
No news the past week
Scandion Oncology announces exercise price for warrants of series TO 2 (Link)
SynAct Pharma publishes Q3 2024 interim results (Link)
No news the past week
No news the past week
No news the past week
No news the past week
Share price development – Danish stocks
On average, the Danish biotech and healthcare stocks delivered a negative return of 3.7%. 5 stocks drove the return with double-digit declines although they did not announce any negative news. Biosergen completed the first cohort in a clinical trial with BSG005. Encouraging results in drug-resistant fungal infections were made. A total of 5 patients were included with 4 of them showing either complete recovery or significant improvements, while the last one died of unrelated causes. Gubra announced the discontinuation of an obesity project with Boehringer Ingelheim, while their 3 other projects with BI continue.
Despite the news Gubra‘s stock contined up last week and continues to be the best-performing stock year-to-date with a return of 246%. Pila Pharma, Zealand Pharma and Y-mAbs Therapeutic have also generated returns of over 100% in 2024. Cessatech is at 98%.
Overview of share price development the past week, year-to-date, and the last twelve month
Nordic Biotech & Healthcare Developments
In the past week, the all-Nordic index Kapital Partner Nordic Healthcare Index (KPHC) declined 1.4% to 64,14. The healthcare index has had a strong performance since the beginning of October last year with an increase of around 7%. The index has performed better than the KPNGX index. However, since August the performance gap has narrowed between them. The index is still behind the large-cap indices. With large caps having outperformed massively in 2024, the performance of the KPHC, with many small and micro caps, is quite good.
The Nordic healthcare stocks (KPHC) vs. C25, S30, and KPNGX the past year
The top three best-performing stocks in the past week
Lidds AB (33%) develops pharmaceutical products based on a patent-protected and clinically tested drug delivery technology. The properties of the products form the basis of LIDDS ‘technology platform for the development of injectable drug products.
ViroGates (33%) is active in medical technology. Today, business operations are conducted in research and development of biomarkers and diagnostic instruments for the healthcare industry. The products are sold under different brands and are used for identification, analysis, and further treatment of diseases, mainly cardiovascular diseases, cancer, and neurological diseases.
Odinwell (23%) is a medtech company. The company specializes in the development of medical devices that are addressed to wound care management. The company is developing a platform for wound care with associated technological aids to analyze and facilitate the process around wound care management. In addition to the main business, associated services are also offered.
Overall, the returns of 23-33% are fairly low compared to previous weeks of the year.
Resources: Refinitiv Eikon, Cision, Nordnet & company websites
